Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846372 | 0.95 | SMN1; SMN2 (0.50) | SMN1; SMN2PDCD1CD274SCN8ACDK1 | |
| SCHEMBL14420391 | 0.83 | HRH4 (0.56) | S1PR1SCN8AMAOBKIF11HRH4 | |
| SCHEMBL16794563 | 0.83 | MAOB (0.59) | S1PR1SCN8AMAOBKIF11HRH4 | |
| SCHEMBL14021244 | 0.81 | HRH4 (0.50) | SMN1; SMN2S1PR1SCN8AMAOBKIF11 | |
| SCHEMBL4423057 | 0.80 | SCN8A (0.51) | S1PR1SCN8AMAOBKIF11HRH4 | |
| SCHEMBL1436108 | 0.79 | PTPN1 (0.54) | SCN8AMAOBMTORALDH1A1 | |
| SCHEMBL1625535 | 0.79 | SMN1; SMN2 (0.64) | SMN1; SMN2PDCD1CD274MCHR1HRH4 | |
| SCHEMBL5867379 | 0.79 | SCN8A (0.47) | S1PR1SCN8AMAOBKIF11HRH4 | |
| SCHEMBL4713071 | 0.79 | SCN8A (0.53) | S1PR1SCN8AMAOBKIF11PPARA | |
| SCHEMBL3542893 | 0.79 | SCN8A (0.47) | SMN1; SMN2S1PR1SCN8AMAOBKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| US-7115616-B2 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-10-03 | — | — | US | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| EP-1175408-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066567-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | SMN1; SMN2 3552/4885PDCD1 3680/4885CD274 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.